You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

Citation Tools

Article menu

Download PDFPDF

XML
Interstitial lung disease
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Maher TM, Kreuter M, Lederer DJ, et al
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
BMJ Open Respiratory Research 2019;6:e000422. doi: 10.1136/bmjresp-2019-000422